enVVeno Medical Corp Material Event - What Happened

Hey there! Let's break down what's been going on with enVVeno Medical Corp. Think of this as me explaining the news to you over a cup of coffee, without all the confusing business talk.

---

1. What happened? (The actual event, in plain English)

Okay, so enVVeno Medical Corp, which is a company focused on developing new treatments for vein problems, just held its Annual Meeting of Stockholders. At this meeting, shareholders voted on several important company matters.

Here's a quick rundown of the key decisions:

• Directors Elected: They re-elected two directors, Matthew M. Jenusaitis and Robert A. Berman, to serve on the Board for another three years.
• Executive Pay Approved (Advisory): Stockholders gave a non-binding thumbs-up to the compensation for the company's top executives.
• Auditors Ratified: They approved CBIZ CPAs P. C. to continue as the company's independent accounting firm for the current fiscal year.
• New Employee Stock Plan Rejected: This is a big one! Stockholders voted against adopting a new 2025 Equity Incentive Plan. This means the company's older 2016 plan will remain in effect for employee stock options and incentives.
• Reverse Stock Split Authority Granted: Another significant vote. Stockholders approved giving the Board of Directors the power to implement a reverse stock split. This means the Board can decide to combine existing shares into fewer, more valuable shares, at a ratio between one-for-five and one-for-thirty-five. They haven't decided to do it yet, but they now have the green light if they choose to.

Basically, shareholders made some key decisions about who runs the company, how executives are paid, who audits their books, how employees are incentivized, and potentially how the company's stock will be structured.

2. When did it happen?

This Annual Meeting was completed on December 11, 2025. The news about the results came out the very next day.

3. Why did it happen? (Context and background)

You know how enVVeno is trying to help people with chronic venous insufficiency (CVI)? That's a fancy way of saying their leg veins don't work right, causing pain and swelling. Their big idea is this VenoValve, which is like a tiny, artificial valve they can put into a patient's leg to fix the problem.

Annual meetings are a standard part of corporate governance. Companies hold them every year to allow shareholders to vote on important issues, elect board members, and have a say in the company's direction.

• Director elections and auditor ratification are routine but essential for good company oversight.
• Executive compensation votes are advisory, giving shareholders a voice on how top management is paid.
• The proposed 2025 Equity Incentive Plan was likely intended to offer new or updated stock-based incentives to employees, which is common for growing companies, especially in biotech, to attract and retain talent. Its rejection means the company will continue to rely on its older plan.
• The reverse stock split authority is often sought by companies whose stock price has fallen significantly. A higher stock price can make the company more attractive to institutional investors and, importantly, help meet minimum price requirements to stay listed on exchanges like NASDAQ.

It's all part of their journey to get this innovative treatment to the market, and these votes impact the company's structure and ability to operate.

4. Why does this matter? (Impact and significance)

This is a pretty big deal because:

• Reverse Stock Split Authority: This is a significant development. If the Board decides to go through with a reverse stock split, it would reduce the number of outstanding shares and increase the price per share. This could help the company meet NASDAQ's minimum bid price requirements, preventing delisting. While it doesn't change the overall value of your investment immediately, it can make the stock appear more "serious" to some investors and potentially improve liquidity.
• Rejected Equity Incentive Plan: The rejection of the new 2025 Equity Incentive Plan could impact the company's ability to attract and retain top talent in the future, as stock options are a key part of compensation in the biotech sector. They'll have to rely on their older 2016 plan, which might not be as flexible or competitive.
• Governance: The re-election of directors and ratification of auditors are important for stable leadership and financial integrity.

In short, these decisions significantly impact the company's financial structure, its ability to incentivize employees, and its standing on the stock market.

5. Who is affected?

• Patients with CVI: While not directly affected by these votes, the company's financial health and ability to attract talent (impacted by the equity plan and potential reverse split) indirectly affect its progress in bringing VenoValve to market.
• enVVeno Medical Corp employees: The rejection of the new equity plan means their future stock-based incentives will continue under the older 2016 plan. The potential for a reverse stock split could also affect how their existing stock options or shares are valued.
• Investors/Shareholders: People who own stock in enVVeno are directly affected. The reverse stock split authority could lead to a higher share price (though fewer shares), and the rejected equity plan might influence future talent acquisition. The election results confirm the current leadership and oversight.
• The Company's Board of Directors: They now have the authority to implement a reverse stock split, giving them a tool to address potential NASDAQ listing issues.

6. What happens next? (Immediate and future implications)

Now that this has happened:

• Reverse Stock Split: The Board of Directors has the authority to implement a reverse stock split, but they haven't decided when or at what exact ratio (within the approved range) to do it. Investors should watch for a separate announcement if and when the Board decides to execute it.
• Equity Incentive Plan: The company will continue to operate under its 2016 Omnibus Incentive Plan for employee stock-based compensation. They might need to consider how to address the need for updated incentive plans in the future.
• Ongoing Operations: The company will continue its work on the VenoValve, with the elected directors and ratified auditors providing oversight.

The immediate future will likely involve the Board considering the timing and specifics of a potential reverse stock split, and the company assessing its long-term incentive strategy.

7. What should investors/traders know? (Practical takeaways)

• Reverse Split Watch: Keep a close eye on any announcements regarding the reverse stock split. While it doesn't change the fundamental value of the company, it can significantly impact the share price and how the stock trades. It's often a move to avoid delisting from major exchanges.
• Employee Incentives: The rejection of the new equity plan could be seen as a minor setback for attracting new talent, but the 2016 plan is still in place.
• Volatility is possible: News like this, especially for smaller biotech companies, can cause the stock price to jump up or down. Don't be surprised by big swings, particularly if a reverse split is announced.
• Do your own research: Always look into the details yourself or consult a financial advisor before making any investment decisions based on news like this. This report is just to help you understand the basics!